Relapsing remitting multiple sclerosis (RRMS) treatment was the one which mostly evolved in the last two decades, mainly with the use of new immunomodulators, including the use of high efficacy oral drugs, such as fingolimod ( The necessity to further increase NEDA criteria validity and sensitivity led to the adoption of new parameters of disease control
The clinicopathological features of GC patients are shown in Supplementary Data 1
The regulation of lipoxygenases by GPX4 led to a dose-dependent inhibition of the total product formation (5-HETE, LTB 4 , 12-HETE, and 15-HETE) in the presence of GPX4 activator compound 102 ( Supplementary Figure S3B )
Designed for dull, sensitive, or uneven-toned skin, this Korean toner delivers luminosity, elasticity, and freshness from the first use
Frias JP, et al
Neuropsychopharmacol 41 , 30803091 (2016)